EuSARC 2018

The Biology of Sarcoma
A Residential Workshop

31 MAY - 2 JUNE

BERTINORO (FC)
ITALY

www.eusarc.com
Welcome to Bertinoro!
The next two days will be full of science, knowledge exchange, and human interaction, with the purpose to shape a network of scientists and clinicians that strongly wish to further commit to solve one of the most terrible problems for human health. Sarcomas differ in many ways from other, more common, types of cancer. They are relatively rare, their natural history is rapid but elusive, their aggressiveness is extreme. In the past decades we have added molecular signature to morphologic diagnosis, and targeted therapies to conventional treatments. Unfortunately, such achievements have not translated into significant prognostic improvements. More recently, immunotherapy has been rediscovered, and metabolic pathways and tumor microenvironment are now being actively investigated and combined with existing knowledge. To improve the outcome of sarcoma patients, a joint effort is desirable, and I hope that this residential workshop will contribute.

Nicola Baldini
EuSARC 2018
Chair
VENUE

CEUB Centro Residenziale Universitario
di Bertinoro
Via Frangipane 6, 47032 Bertinoro (FC)
tel. +39 0543.446500 – fax +39 0543.446599
Organizing Secretariat:
Monica Michelacci: mmichelacci@ceub.it

REGISTRATION

Registration, including transfer from/to
Bologna, coffee-breaks, lunches, social
dinner and welcome cocktail: 90 €.
A maximum of 80 attendees will be hosted.
Attendees will register upon arrival in
Bertinoro.

TRANSFER

A bus will be organized from/to Bologna
International Airport and Railway Station
for all attendees on May 31 and June 2,
respectively (free service, mandatory
advance registration)

ACCOMMODATION

Board and lodging will be available to
all attendees at Ce.U.B. in Bertinoro.
    Single room, per night: 45 €
        (including breakfast).
    Double room, per night: 35 €
        (including breakfast).

SOCIAL PROGRAM

Coffee breaks and lunches are included
in the accommodation fee.
A welcome cocktail will be offered to
all registered attendees on May 31 at
19.30.
Social dinner: on June 1 at the Ca’ de Be’
restaurant.
CHAIR
Nicola Baldini
University of Bologna and Istituto Ortopedico Rizzoli

SCIENTIFIC COMMITTEE
Sofia Avnet
Istituto Ortopedico Rizzoli

Silvia Cammelli
University of Bologna and S. Orsola-Malpighi University Hospital

Davide Maria Donati
University of Bologna and Istituto Ortopedico Rizzoli

Costantino Errani
Istituto Ortopedico Rizzoli

Stefano Fanti
University of Bologna and S. Orsola-Malpighi University Hospital

Pier Luigi Lollini
University of Bologna

Alessandra Longhi
Istituto Ortopedico Rizzoli

Enrico Lucarelli
Istituto Ortopedico Rizzoli

Cristina Nanni
University of Bologna and S. Orsola-Malpighi University Hospital

Maria Abbondanza Pantaleo
University of Bologna and S. Orsola-Malpighi University Hospital

Andrea Pession
University of Bologna and S. Orsola-Malpighi University Hospital

Piero Picci
Istituto Ortopedico Rizzoli

Katia Scotlandi
Istituto Ortopedico Rizzoli

Massimo Serra
Istituto Ortopedico Rizzoli

SCIENTIFIC SECRETARIAT
Francesca Schirru
University of Bologna and Istituto Ortopedico Rizzoli
AIMS

• INCREASE KNOWLEDGE - To provide a forum to increase knowledge in sarcoma biology and pathophysiology in order to offer a more effective patient care.

• FILL THE GAP - To fill the gap between biological and clinical research.

• NETWORK - To establish and consolidate a network of scientists who are keen to collaborate in the field of sarcoma.

• PROMOTE ACTIONS - To promote actions to encourage and support in-training scientists in sarcoma research.

• RAISE PUBLIC AWARENESS - To raise public awareness on the clinical relevance of sarcomas and the importance of promoting sarcoma research.
SCIENTIFIC PROGRAM
THURSDAY, 31 MAY

18.00
Opening
Nicola Baldini

18.15
Lecture: “The role of nerves in cancer initiation and progression”
Hubert Hondermarck, University of Newcastle, Callaghan, (AU)

19.30
Welcome Cocktail

FRIDAY, 1 JUNE

SESSION 1

8.30
TUMOR HETEROGENEITY
(Valentina Indio, Hubert Hondermarck)

8.30
Invited lecture: “Analytical methods to assess tumor heterogeneity”
Dominique Heymann, INSERM Université de Nantes, Nantes FR

9.00
Round cell sarcomas other than Ewing sarcoma: a single institution experience
Gambarotti M, Palmerini E, Benini S, Picci P, Longhi A, Donati D, Sbaraglia M, Righi A, Dei Tos AP (Bologna, Italy)

9.15
Clonal and sub-clonal heterogeneity of a murine model of osteosarcoma
Gambera S, Álvaro MM, Teresa CG, Arantzazu AG, Javier GC, (Madrid, Spain)

9.30
Osteosarcoma: the emerging role of microenvironment and metabolism
Avnet S, Perut F, Di Pompo G, Lemma S, Cortini M, Baldini N (Bologna, Italy)

9.45
Role of autophagy in the crosstalk between osteosarcoma and the bone microenvironment
THE ROLE OF STROMA: VASCULAR NICHE, IMMUNE CELLS, MESENCHYMAL STROMAL CELLS
(Will English, Dominique Heymann)

Invited lecture: “Vascular niches in bone: heterogeneity and therapeutic potential”
Anjali Kusumbe, University of Oxford, Oxford UK

Mesenchymal stromal cells enhance metastasis formation in osteosarcoma
Lemma S, Avnet S, Grisendi G, Dominici M, Heymann D, Baldini N (Bologna, Italy)

Toward rhabdomyosarcoma microenvironment dissection: cancer associated fibroblast investigation
D’Agostino S, Frasson C, Tombolan L, Rampazzo, Persano L, Bisogno G, Gamba PG, Pozzobon M (Padova, Italy)

Osteosarcoma derived extracellular vesicles mediated epigenetic alterations in mesenchymal stem cells
Mannerström B, Kornilov R, Chowdhury I M, Seppänen-Kajjansinkko R, Kaur S. (Helsinki, Finland)

Extracellular nanovesicles secreted by human osteosarcoma cells promote angiogenesis
Perut F, Roncuzzi L, Massa A, Torreggiani E, Zini N, Baldini N (Bologna, Italy)

Can osteoclasts degrade cartilage in sarcoma?
Larrouy OL, Gibbons M, Athanasou NA, Snelling SJB, Knowles HJ (Oxford, UK)

Why does a 12-year-old get osteosarcoma and then show evidence of coronary artery disease by age 32?
Baker L, D.O. Antalis E P, (Ann Arbor, USA)

Coffee Break

Lunch
FRIDAY, 1 JUNE

SESSION 3

NEW THERAPIES
(Julia Visgauss, Alessandra Longhi)

INVITED LECTURE: “NEW THERAPIES WITH ANTI-TUMOR ACTIVITY IN SARCOMA STEM CELLS”
René Rodríguez, Instituto Universitario de Oncología de Asturias, ES

14.00

NF-κB pathway as a therapeutic target to inhibit mesenchymal stromal reaction to tumor acidosis and impair osteosarcoma progression

14.45

In vitro efficacy of keratin based bimodal nanoparticles: chemotherapy and photodynamic therapy to address drug toxicity and chemoresistance
Martella E, Ferroni C, Guerrini A, Lucarelli E, Columbaro M, Varchi G, Tavanti E, Duchi S (Bologna, Italy)

15.00

Targeting Ewing sarcoma by empowered killer mesenchymal progenitors

15.45

Oncolytic adenoviruses weaponized with immunostimulatory molecules for the treatment of osteosarcoma

16.30

Combined immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in a murine model of osteosarcoma
Álvaro M-M, Stefano G, Ana Judith P-B, Elena C, Alicia G, Javier G-C (Madrid, Spain)

Coffee Break and Poster Session
INVITED LECTURE: “GUT MICROBIOTA PROFILING AND RESPONSE TO CHEMOTHERAPY”
Silvia Turroni, Università di Bologna, Bologna IT

Sarcoma primary cell lines as a platform to screen anticancer compounds able to target cancer stem cells
Rey V, Fernández-Nevado L, Menendez S T, Estupiñan O, Rodriguez R (Oviedo, Spain)

Detection of an actionable mutation of c-kit in extraskeletal myxoid chondrosarcoma

Immune microenvironment profiling of gastrointestinal stromal tumors

Characterization of tumor microenvironment in extraskeletal myxoid chondrosarcoma (EMC)

Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma

Social Dinner, Ca’ de Bè restaurant
SATURDAY, 2 JUNE

SESSION 5

8.30
Invited lecture: “Germline genetics of Ewing sarcoma susceptibility and progression”
Thomas Grünewald, Ludwig Maximilian Universität, München, DE

9.00
Interleukin-34 as a potential therapeutic target for the treatment of osteosarcoma
Schiavone K, Brown H.K, v Heymann M F, Robin Y, Heymann D (Sheffield, UK)

9.15
ATRX deficiency in osteosarcoma predicts enhanced sensitivity to human recombinant trail
Visgauss JD, Somarelli J, Bartholf-DeWitt S, Camp T, Altunel E, Kerr D, Eward W (Toronto, Canada)

9.30
Pazopanib in osteosarcoma metastatic patients: report of 9 patients treated at the Rizzoli Institute

9.45
The role of neuropilin-1 and VEGF isoforms and their potential as predictive biomarkers of response to vascular-targeted therapies
Thomas RHE, Fisher M, English WE, Tozer GM, Kanthou C (Sheffield, UK)

10.00-10.30
Coffee Break
CANCER METABOLISM AND EPIGENETIC
(Sofia Avnet, Marc Garcia-Moure)

Invited lecture: “Functional and molecular imaging in cancer”
Dario Longo, Università di Torino, Torino, IT

Targeting lipid metabolism as a novel osteosarcoma treatment
Cortini M, Columbaro M, Avnet S, Armirotti A, Baldini N (Bologna, Italy)

A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in the Therapy of bone sarcomas

Exploiting novel mitochondrial targets in cisplatin resistant osteosarcoma
Vianello C, Cocetta V, Catanzaro D, Giacomello M, Montopoli M (Padova, Italy)

Study of the molecular mechanisms of BCOR alterations in subsets of pediatric sarcomas through gene editing

EuSARC Round Table
“Sarcoma Research: present and future”
(Nicola Baldini and Dominique Heymann)

Lunch and Departure
POSTER COMMUNICATIONS

P1 Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxobrosarcoma invasion identified by global protein expression profiling.
Kikuta K, Kubota D, Yoshida A, Morioka H, Nakamura M (Tokyo, Japan)

P2 Photoactivation in the near-infrared Spectrum applied to a 2D and 3D model containing nanoparticles-loaded Mesenchymal Stem Cells and osteosarcoma cells induces extensive cell death.

P3 High expression of SOX2 characterizes high-risk Ewing sarcoma tumors.

P4 CXCR4 : potential target in osteosarcoma?
Bientinesi E, Pollino S, Pazzaglia L, Dozza B, Palmerini E, Enrico Lucarelli, Benassi MS. (Bologna, Italy)

P5 Germline polymorphisms involved in drug response and treatment-related toxicity in osteosarcoma.

P6 Acridine Orange combined photodynamic therapy and surgery as a novel approach to treat feline injection-site sarcoma.
Costa F, Avnet S, Martano M, Morello E, Paolo Buracco, Katsuyuki Kusuzaki, Nicola Baldini (Bologna, Italy)

P7 Salinomycin treatment affects chondrosarcoma cell viability in spheroid-based 3D model.
Perut F, Sbrana FV, Avnet S, De Milito A, Baldini N (Bologna, Italy)

P8 Expression of H3F3A mutation in the mixed cell population of Giant Cell Tumor of Bone.
Okere B, Panza E, Lemma S, Errani C, Avnet S, Baldini N (Bologna, Italy)
P9 **Gut microbiota in osteosarcoma and chemotherapy: a pilot study.**
Falzetti L, Lemma S, Avnet S, Candela M, Turroni S, Baldini N (Bologna, Italy)

P10 **Novel c-KIT exon 9 mutations in GIST: is Imatinib good for bad?**
Laurini E, Aulic S, Marson D, Fermeglia M, Riboni R, Lucioni M, Dellera E, Alessiani M, Perfetti V, Pricl S (Trieste, Italy)

P11 **Specific packaging of microRNAs from osteosarcoma cell-derived exosomes affects tumor microenvironment: implications in tumor progression.**

P12 **Clinical benefit on sarcomas after systemic cellular viroimmunotherapy.**

P13 **Different decellularization methods to characterize the extracellular matrix of rhabdomyosarcoma and healthy muscle tissue.**
D'Agostino S, Saggio M, Muraca M, Gamba P, Pozzobon M (Padova, Italy)